285 related articles for article (PubMed ID: 25656918)
21. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors.
Fagervall I; Ross SB
Biochem Pharmacol; 1986 Apr; 35(8):1381-7. PubMed ID: 2870717
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
Barbelivien A; Nyman L; Haapalinna A; Sirviö J
Pharmacol Toxicol; 2001 Jun; 88(6):304-12. PubMed ID: 11453370
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
[TBL] [Abstract][Full Text] [Related]
24. The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats.
Wooters TE; Bardo MT
Behav Pharmacol; 2007 Nov; 18(7):601-8. PubMed ID: 17912044
[TBL] [Abstract][Full Text] [Related]
25. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
[TBL] [Abstract][Full Text] [Related]
26. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
27. Psoralen, a mechanism-based inactivator of CYP2B6.
Ji L; Lu D; Cao J; Zheng L; Peng Y; Zheng J
Chem Biol Interact; 2015 Oct; 240():346-52. PubMed ID: 26335194
[TBL] [Abstract][Full Text] [Related]
28. The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19.
Chen Y; Liu HF; Liu L; Nguyen K; Jones EB; Fretland AJ
Xenobiotica; 2010 Aug; 40(8):536-46. PubMed ID: 20528624
[TBL] [Abstract][Full Text] [Related]
29. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.
Murphy DL; Lipper S; Slater S; Shiling D
Psychopharmacology (Berl); 1979 Apr; 62(2):129-32. PubMed ID: 111275
[TBL] [Abstract][Full Text] [Related]
30. Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.
Wang PF; Neiner A; Kharasch ED
Drug Metab Dispos; 2020 Jun; 48(6):438-445. PubMed ID: 32238417
[TBL] [Abstract][Full Text] [Related]
31. Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice.
Boden R; Botting R; Coulson P; Spanswick G
Br J Pharmacol; 1984 May; 82(1):151-4. PubMed ID: 6428496
[TBL] [Abstract][Full Text] [Related]
32. A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6.
Walsky RL; Obach RS
Drug Metab Dispos; 2007 Nov; 35(11):2053-9. PubMed ID: 17682072
[TBL] [Abstract][Full Text] [Related]
33. Amine oxidase released into plasma of rats treated with hepatotoxin allyl formate.
Obata T; Egashira T; Yamanaka Y
Res Commun Chem Pathol Pharmacol; 1989 Oct; 66(1):69-85. PubMed ID: 2515565
[TBL] [Abstract][Full Text] [Related]
34. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.
Fowler CJ; Oreland L; Callingham BA
J Pharm Pharmacol; 1981 Jun; 33(6):341-7. PubMed ID: 6115003
[No Abstract] [Full Text] [Related]
35. Different sensitivity of mitochondrial and cytosolic monoamine oxidases to in vivo but not in vitro inhibition by specific irreversible inhibitors.
Moskvitina TA; Medvedev AE
Med Sci Monit; 2001; 7(1):17-9. PubMed ID: 11208486
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory Effects of Garcinia cambogia Extract on CYP2B6 Enzyme Activity.
Yu JS; Choi MS; Park JS; Rehman SU; Nakamura K; Yoo HH
Planta Med; 2017 Jul; 83(11):895-900. PubMed ID: 28288493
[TBL] [Abstract][Full Text] [Related]
38. In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase.
Kamel A; Colizza K; Gunduz M; Harriman S; Obach RS
Xenobiotica; 2012 Apr; 42(4):355-62. PubMed ID: 22106962
[TBL] [Abstract][Full Text] [Related]
39. Imperatorin is a mechanism-based inactivator of CYP2B6.
Zheng L; Cao J; Lu D; Ji L; Peng Y; Zheng J
Drug Metab Dispos; 2015 Jan; 43(1):82-8. PubMed ID: 25378064
[TBL] [Abstract][Full Text] [Related]
40. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.
Polasek TM; Elliot DJ; Lewis BC; Miners JO
J Pharmacol Exp Ther; 2004 Dec; 311(3):996-1007. PubMed ID: 15304522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
